Medicinova (MNOV) Net Income towards Common Stockholders (2010 - 2025)

Medicinova (MNOV) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$2.8 million in Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 8.55% year-over-year to -$2.8 million in Q4 2025; TTM through Dec 2025 was -$12.9 million, a 7.52% decrease from a year earlier, with the FY2025 full-year figure at -$9.5 million, up 21.38% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$2.8 million, up from -$3.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for MNOV reached as high as -$226526.0 in Q1 2021 and fell as low as -$85.4 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$7.2 million across 5 years, with a median of -$3.2 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders plunged 2745.49% in 2023 and soared 96.42% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$2.1 million in 2021, then plunged by 43.0% to -$3.0 million in 2022, then plunged by 2745.49% to -$85.4 million in 2023, then surged by 96.42% to -$3.1 million in 2024, then grew by 8.55% to -$2.8 million in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$2.8 million in Q4 2025, -$3.2 million in Q3 2025, and -$3.6 million in Q2 2025.